Table 1.
Antibody | FDA-approved regimens | EMA-approved regimens |
---|---|---|
Bevacizumab | In combination with i.v. 5-FU-based chemotherapy for first- or second-line treatment | In combination with fluoropyrimidine-based chemotherapy |
Cetuximab | As a single agent in EGFR-expressing mCRC after failure of both irinotecan- and oxaliplatin-based regimens or in patients who are intolerant to irinotecan-based regimens In combination with irinotecan in EGFR-expressing mCRC in patients who are refractory to irinotecan-based chemotherapy Not recommended for the treatment of mCRC with KRAS mutations in codons 12 or 13 | In combination with chemotherapy or as a single agent in patients with EGFR-expressing, KRAS wild-type mCRC who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan |
Panitumumab | Single agent for EGFR-expressing mCRC with disease progression or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens Not recommended for the treatment of mCRC with KRAS mutations in codons 12 or 13 | Monotherapy in EGFR-expressing mCRC with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens |
EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; FDA, Food and Drug Administration; 5-FU, 5-fluorouracil; i.v., intravenous; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; mCRC, metastatic colorectal cancer.
Sources: http://www.emea.europa.eu/, http://www.fda.gov/.